
What if some people struggling with obesity aren’t producing enough of the very hormone that medications like Mounjaro and Zepbound are designed to mimic?
Researchers at Mayo Clinic have identified a distinct biological pattern in people living with obesity that could help explain why some patients experience extraordinary weight loss with GLP-1 medications while others see more modest results. And the findings, published in the November 2026 issue of Gastroenterology, offer another compelling reason to rethink how we understand and treat obesity.
For years, patients have been told that weight management comes down to eating less and moving more. But research continues to reveal something far more complicated happening beneath the surface, including differences in how our bodies produce the hormones responsible for regulating hunger and fullness.
Some People May Have a Broken Fullness Signal
Our bodies naturally produce a hormone called GLP-1, which helps regulate blood sugar, slows the movement of food out of the stomach, and communicates with the brain about hunger and fullness. It’s one of the hormonal pathways targeted by medications like Ozempic, Wegovy, Mounjaro, and Zepbound. But not everyone’s body produces or responds to these signals in the same way.
Mayo Clinic researchers studied 483 adults living with obesity, measuring how quickly food left their stomachs, how hungry they felt after eating, and how much GLP-1 their bodies released.
They discovered that approximately 27% of participants had a particularly interesting combination of biological characteristics. Their stomachs emptied food relatively quickly, they experienced more hunger after eating, and their bodies produced unexpectedly low levels of GLP-1.
In other words, some of these patients appeared to be working with a weaker hormonal system for regulating fullness, potentially making it harder to stay satisfied after a meal.
And researchers found evidence that the problem might go beyond simply having low hormone levels in the bloodstream.
Their Bodies Appeared to Be Making Less GLP-1
In a smaller follow-up investigation involving intestinal tissue samples from 31 patients, researchers found that people with this particular obesity subtype had approximately 45% lower activity of the gene involved in producing GLP-1 and 50% lower activity of a gene involved in producing another fullness hormone called PYY.
That doesn’t mean researchers proved these patients produce exactly 45% less GLP-1. But it does suggest that, for some people, the machinery responsible for making these hormones may not be functioning the same way.
Think about that for a moment. Two people can eat the same meal, have similar body weights, and still experience very different biological signals telling them when they’ve had enough.
One person’s body may send a strong message that they’re satisfied. Another person’s body may send a much weaker message, leaving them hungry again sooner.
Sadly, we have spent decades treating those two people as though they simply needed the same advice about willpower.
The Zepbound Results Were Remarkable
Here’s where the research gets especially interesting. Researchers also examined 61 participants who subsequently received tirzepatide, the active ingredient in Mounjaro and Zepbound, to see whether their biological differences were associated with different treatment outcomes.
After six months, the results were astounding.
Patient group
Average weight loss
Low GLP-1, faster stomach emptying
21.5%
Other biological groups combined
11.7%
The patients with the low-GLP-1 pattern lost nearly twice as much weight on average. For someone starting at 250 pounds, that’s the difference between losing approximately 54 pounds and 29 pounds in six months.
These findings suggest that tirzepatide may be particularly effective in patients whose natural appetite-regulating signals are impaired. Rather than simply suppressing appetite, the medication may be helping compensate for a biological pathway that isn’t functioning as expected.
There is an important limitation to note here. The treatment analysis involved only 61 people and was observational, not a randomized clinical trial designed to prove that low GLP-1 causes a stronger response. Larger studies will be needed to confirm the findings.
This Is Why Obesity Treatment Cannot Be One-Size-Fits-All
I’ve said for years that obesity is not one disease with one cause. It’s a collection of biological problems that can look similar on the outside but behave very differently on the inside. This research adds another piece to that puzzle.
It doesn’t mean everyone living with obesity has a GLP-1 deficiency, and it certainly doesn’t mean a simple blood test can tell you which medication will work best. We’re not there yet, but I believe it does move us closer to a future where obesity treatment is guided by what’s happening inside a patient’s body rather than relying entirely on trial and error.
And perhaps most importantly, it challenges the idea that everyone experiences hunger and fullness the same way.
For those who have spent a lifetime at war with their own hunger, watching others walk away from the table satisfied while their own bodies continue to ask for more, this research offers something they have been denied for far too long. An explanation. The possibility that what they were taught to see as a failure of character was, all along, a difference in biology. That the hunger they carried was real, even when nobody believed them.
I’ve said it before, and I’ll keep saying it until the world understands. Patients don’t fail treatments. Treatments fail patients. And perhaps the greatest injustice in obesity medicine has been our insistence on treating every patient as though they were fighting the same disease, then blaming them when the same treatment didn’t work.
The future of obesity medicine isn’t simply about developing more powerful drugs. It’s about finally understanding the people who need them. Because behind every number on a scale is a human being who deserves more than another lecture about willpower. They deserve answers. They deserve treatment that recognizes and understands their biology. And above all, they deserve to know that their struggle was never proof of their value as a human.

